US › Healthcare

Inhibikase Therapeutics Inc (IKT)

US · Healthcare · Biotechnology

$1.65-9.84%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-19.6M

EPS

$-0.11

EPS estimate

$-0.09

EPS came in at -0.11 against a street estimate of -0.09 — a miss of 22.2%.

Key statistics

Market cap

$230.2M

Forward P/E

0.0

P/B

1.96

Book value

$0.88

EPS (TTM)

$-0.43

52-week high

$2.61

52-week low

$1.33

50-day MA

$2.24

200-day MA

$1.95

Beta

0.90

Analyst view

Analysts rate Inhibikase Therapeutics Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $6.00.

Shareholding

Insiders

6.09%

Institutions

89.73%

Largest institutional holders

Fund	Stake
Sands Capital Ventures, LLC	9.33%
Soleus Capital Management, L.P.	7.79%
Trails Edge Capital Partners, LP	6.49%
Fairmount Funds Management LLC	6.18%
BlackRock Inc	5.57%
Kalehua Capital Management LLC	5.48%
ADAR1 Capital Management LLC	5.29%
Blackstone Inc	4.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Inhibikase Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.